THE STATUS OF ANAPHYLAXIS AT THE ALLERGY AND CLINICAL IMMUNOLOGY DEPARTMENT, BACH MAI HOSPITAL, 2024-2025
Main Article Content
Abstract
Objectives: To describe the epidemiological, clinical, and laboratory characteristics, suspected triggers, and initial management of anaphylaxis at the Center for Allergy and Clinical Immunology, Bach Mai Hospital, during 2024-2025.
Subjects and methods: A cross-sectional descriptive study was conducted on 325 inpatients diagnosed with anaphylaxis at the Center for Allergy and Clinical Immunology, Bach Mai Hospital, from July 1, 2024, to June 30, 2025. Data on demographic characteristics, location of symptom onset, initial responders and management, anaphylaxis severity, suspected triggers, initial clinical manifestations, and selected laboratory findings were collected and analyzed descriptively.
Results: Females accounted for 66.8% of patients, with a mean age of 41.39 ± 17.42 years. Anaphylaxis most commonly occurred at home (57.5%), and the majority of patients received initial management by healthcare professionals (98.2%) at various healthcare facilities. Grade II anaphylaxis was the most frequent (55.4%). Most cases were classified as anaphylaxis with unidentified triggers (91.4%). Cutaneous and mucosal manifestations were the most common initial symptoms (83.1%), followed by respiratory symptoms (53.2%), while gastrointestinal and cardiovascular symptoms were less frequent. Elevated total IgE was found in 34.8% of patients, renal impairment in 5.5%, and elevated CRP in 24.5%.
Conclusions: Anaphylaxis at Bach Mai Hospital predominantly occurred outside healthcare settings and was mainly of moderate severity. Although patients demonstrated appropriate healthcare-seeking behavior and initial management was largely guideline-adherent, the high proportion of unidentified triggers highlights limitations in exposure history assessment and patient awareness. Strengthening patient education and post-anaphylaxis follow-up is essential to improve long-term management and prevent recurrence
Article Details
Keywords
Anaphylaxis, initial management, Adrenaline, onset of symptoms, Bach Mai Hospital.
References
[2] Jahnz-Rozyk K, Raciborski F, Śliwczyński A.M et al. Anaphylaxis in Poland: the epidemiology and direct costs. Postepy Dermatol Alergol, 2017, 34 (6): 573-579. doi: 10.5114/pdia.2017.70361.
[3] Lee M.H, Roh E.J, Jung Y.M et al. Characteristics of anaphylaxis patients who visited emergency departments in Korea: Results from a national emergency department information system. PloS One, 2022, 17 (4): e0266712. doi: 10.1371/journal.pone.0266712.
[4] Simons F.E.R, Ardusso L.R.F, Bilò M.B et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J, 2011, 4 (2): 13-37. doi: 10.1097/WOX.0b013e318211496c.
[5] Nguyễn Thị Thùy Ninh. Nghiên cứu tình trạng sốc phản vệ ở Bệnh viện Bạch Mai. Luận văn thạc sỹ y học, Trường Đại học Y Hà Nội, 2014.
[6] Thái Nguyễn Hoàng. Nghiên cứu tình trạng phản vệ tại Bệnh viện Bạch Mai. Luận văn thạc sỹ y học, Trường Đại học Y Hà Nội, 2020.
[7] De Martinis M, Sirufo M.M, Suppa M et al. Sex and gender aspects for patient stratification in allergy prevention and treatment. Int J Mol Sci, 2020, 21 (4): 1535. doi: 10.3390/ijms21041535.
[8] Salvati L, Vitiello G, Parronchi P. Gender differences in anaphylaxis. Curr Opin Allergy Clin Immunol, 2019, 19 (5): 417-424. doi: 10.1097/ACI.0000000000000568.
[9] Turner P.J, Jerschow E, Umasunthar T et al. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract, 2017, 5 (5): 1169-1178. doi: 10.1016/j.jaip.2017.06.031.
[10] Nduwimana M.J, Liu S.W, Goldberg E.M et al. Characteristics and outcomes of anaphylaxis in emergency department visits among older adults. J Allergy Clin Immunol Pract, 2025, 13 (8): 2014-2024.e4. doi: 10.1016/j.jaip.2025.04.023.
[11] Cardona V, Ansotegui I.J, Ebisawa M et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J, 2020, 13 (10): 100472. doi: 10.1016/j.waojou.2020.100472.
[12] Shaker M.S, Wallace D.V, Golden D.B.K et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. J Allergy Clin Immunol, 2020, 145 (4): 1082-1123. doi: 10.1016/j.jaci.2020.01.017.
[13] Le M, Gabrielli S, Clarke A et al. Emergency management of anaphylaxis due to an unknown trigger: an 8-year follow-up study in Canada. J Allergy Clin Immunol Pract, 2019, 7 (4): 1166-1173.e1. doi: 10.1016/j.jaip.2018.11.015.
[14] Muraro A, Roberts G, Worm M et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy, 2014, 69 (8): 1026-1045. doi: 10.1111/all.12437.